192570-33-5

Usage

Uses

Used in Pharmaceutical Development:
5-Fluoroquinazoline-2,4(1H,3H)-dione is used as a potential drug candidate for the development of therapeutic agents. Its unique structure and the presence of a fluorine atom may contribute to its biological activity, making it a promising compound for further exploration in medicinal chemistry.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 5-Fluoroquinazoline-2,4(1H,3H)-dione is utilized as a subject of study to investigate its pharmacological properties and potential applications. 5-Fluoroquinazoline-2,4(1H,3H)-dione's quinazoline core and fluorine substitution may offer insights into structure-activity relationships and the design of novel therapeutic agents.
Used in Drug Discovery:
5-Fluoroquinazoline-2,4(1H,3H)-dione is employed in drug discovery processes to identify its potential as a lead compound for the treatment of various diseases. Its quinazoline-2,4-dione scaffold and fluorinated nature may provide a foundation for the optimization of drug candidates with improved potency, selectivity, and pharmacokinetic properties.
Used in Biochemical Studies:
In biochemical research, 5-Fluoroquinazoline-2,4(1H,3H)-dione serves as a tool to explore its interactions with biological targets, such as enzymes, receptors, or other macromolecules. Understanding these interactions can provide valuable information on the compound's mechanism of action and its potential therapeutic applications.
Used in Chemical Synthesis:
5-Fluoroquinazoline-2,4(1H,3H)-dione is utilized in chemical synthesis for the preparation of derivative compounds with modified structures. These derivatives may exhibit enhanced or novel pharmacological properties, broadening the scope of potential applications for this class of compounds in various industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 434-76-4 2-amino-6-fluorobenzoic acid 
• 57-13-6 urea 
• 77326-36-4 2-amino-6-fluorobenzonitrile 
• 68-12-2 N,N-dimethyl-formamide 
• 917-61-3 sodium isocyanate 
• 124-38-9 carbon dioxide 

Downstream Products

• 192570-36-8 1-(3,5-di-O-p-toluoyl-2-deoxy-α,β-D-erythro-pentofuranosyl)-5-fluoro-quinazoline-2,4(3H)-dione 
• 192570-51-7 1-[2-deoxy-5-(4,4'-dimethoxytrityl)-β-D-erythro-pentofuranosyl]-5-fluoro-quinazoline-2,4(3H)-dione 
• 192570-56-2 1-[2-deoxy-5-(4,4'-dimethoxytrityl)-α-D-erythro-pentofuranosyl]-5-fluoro-quinazoline-2,4(3H)-dione 
• 769158-33-0 2-((2-chloro-5-fluoro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 
• 87611-00-5 2,4-dichloro-5-fluoroquinazoline 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES

This disclosure provides a process for preparing 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones, specially provides a method for preparing the compound of Formula I, and the method comprises the step of reacting the compound of Formula II with the compound o

Facile and efficient synthesis of quinazoline-2,4(1H,3H)-diones through sequential hydrogenation condensation

The heterocyclizations from various methyl (2-nitrobenzoyl)carbamates to substituted quinazoline-2,4(1H,3H)-diones under hydrogenation conditions were investigated in this study. In the presence of p-toluenesulfonic acid monohydrate in methanol, various q

NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICES CONTAINING THEM

The present invention relates to compounds of the general formula (11), to a material for an organic electroluminescence device comprising ot least one of these compounds, to an organic electroluminescence device comprising at least one of these compounds

Carbon Dioxide Mediated Novel Synthesis of Quinazoline-2,4(1H,3H)-dione in Water

A novel, efficient, and scalable CO2 mediated synthesis of quinazoline-2,4(1H,3H)-dione was developed by a simple cyclization of 2-aminobenzonitrile with DMF in water as the solvent. This is the first report of its kind. DMF was used as the necessary carbon source in the synthesis of quinazoline-2,4(1H,3H)-dione. This synthetic protocol is very efficient; it gives >99% conversion with excellent selectivity. The product was isolated by filtration because of the highly insoluble nature of quinazoline-2,4(1H,3H)-dione in water. The co-product, dimethyl amine, also has industrial importance, and the CO2 that is used can be recycled. This protocol has wide-spread applications in the syntheses of benzimidazole and benzothiazole.

La-Mg mixed oxide as a highly basic water resistant catalyst for utilization of CO2 in the synthesis of quinazoline-2,4(1H,3H)-dione

The synthesis of quinazoline-2,4(1H,3H)-dione was done by direct utilization of CO2 in the cyclization of 2-aminobenzonitrile (2-ABN) using lanthanum magnesia mixed oxide (La-Mg MO) as a strong basic catalyst under mild reaction conditions in water. It gave a conversion of ～92% with 100% selectivity at 140 °C in 14 h. La-Mg MO was prepared by hydrothermal method using urea as homogeneous precipitating agent. The catalyst was characterized by different analytical techniques like BET, XRD, FT-IR, SEM, and TGA, and the basicity by CO2-TPD and acidity by NH3 TPD. Various reaction parameters were studied to predict the reaction mechanism and kinetics. The reaction follows the Langmuir-Hinshelwood-Hougen-Watson (LHHW) type kinetics model with an apparent activation energy of 23.3 kcal mol-1. The catalyst was recycled three times with an insignificant change in activity. The overall process is clean and green.

Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors

Poly(ADP-ribose)polymerase-1 (PARP-1) has emerged as a promising anticancer drug target due to its key role in the DNA repair process. In this work, a novel series of 1-benzyl-quinazoline-2,4(1H,3H)-dione derivatives were designed and synthesized as human PARP-1 inhibitors, structure-activity relationships were conducted and led to a number of potent PARP-1 inhibitors having IC50 values of single or double digit nanomolar level. Compound 7j was a potent PARP-1 and PARP-2 inhibitor and it could selectively kill the breast cancer cells MX-1 and MDA-MB-468 with mutated BRCA1/2 and PTEN, respectively, in comparison with homologous recombination proficient cell types such as breast cancer cells MDA-MB-231. In addition, compound 7j displayed the strongest potentiation effect on temozolomide in MX-1 cells (PF50 = 3.77) in this series of PARP-1 inhibitors.

Synthesis of 5-and 7-fluoroquinazolin-4(1H)-ones

5-Fluoroquinazoline-2,4-diones and their 2-thio analogs were obtained from 6-fluoroanthranilic acid. Two convenient routes to 5-fluoroquinazolin-4-ones involved cyclocondensation of 6-fluoroanthranilamide with acid chlorides (anhydrides) or with aromatic (heterocyclic) aldehydes. A method for the synthesis of 7-fluoroquinazolin-4-one from 2,4-difluorobenzoic acid was proposed.

Tripler stability of oligodeoxynucleotides containing substituted quinazoline-2,4-(1H,3H)-dione

Triple helical structures can be observed between double-stranded nucleic acids and a third strand through the formation of Hoogsteen hydrogen bond. We report here the use of quinazoline-2,4-dione derivatives as substitutes for thymine in TA*T triplets. The synthesis and the characterization of monochloro derivatives of quinazoline-2,4-dione as well as 5-fluoro and 6-nitro substituted quinazoline rings are described. The ability of the various modified bases to promote the formation of triplexes was reached by thermal denaturation studies.